The role of the PAFc subunit Cdc73 in normal hematopoiesis and transformation

PAFc亚基Cdc73在正常造血和转化中的作用

基本信息

项目摘要

Epigenetic modifications of regulatory elements on chromatin profoundly impact gene expression and play a role in processes such as cellular differentiation and transformation. These post-translational modifications occur on DNA and histones and are mediated by epigenetic modifying proteins. The Polymerase Associated Factor complex (PAFc) is an epigenetic modifying complex necessary for the deposition of several epigenetic modifications associated with transcriptional activation (including H2Bub, H3K4me and H3K79me). We have recently shown that the PAFc is essential for human leukemias harboring rearrangements of the Mixed Lineage Leukemia (MLL) gene as well as several other subtypes of acute myeloid leukemia (AML). Our preliminary data shows the PAFc is also necessary for fetal hematopoiesis. Further, we found the PAFc is regulated by interaction with the H3K9 methyltransferase SETDB1, which suppresses leukemic transformation. Objective: The role of the PAFc in hematopoiesis and the distinct epigenetic functions required for cellular transformation remains unclear. Our preliminary studies have revealed a novel interaction between the PAFc and an H3K9 methyltransferase, SETDB1 and a role for the PAFc in fetal hematopoiesis. We hypothesize that the PAFc-SETDB1 interaction promotes hematopoietic differentiation and that interference of this interaction aids in transformation by promoting transcriptional activation of a gene program blocking differentiation. Specific Aims: We aim to (1) Characterize the role of the PAFc subunit, Cdc73, in hematopoiesis, (2) Validate the role of the PAFc interaction partner, SETDB1, as a hematopoietic tumor suppressor and (3) Define the mechanism by which SETDB1 modulates PAFc mediated transcriptional activation. Study Design: We have developed a mouse model that allows for the conditional deletion and subsequent characterization of the PAFc subunit, Cdc73, in adult hematopoietic tissues. We will use mutants of CDC73 that alter interaction with SETDB1, as well as overexpression and knock down to evaluate the role of SETDB1 and the PAFc-SETDB1 interaction in differentiation. We will also use a combination of biochemical, molecular and high throughput methods to query the transcriptional consequences of SETDB1 interaction with the PAFc. Health Impact: Epigenetic modifiers are recognized as critical players in cellular differentiation. They also play important roles in hematologic disease and have been validated as viable therapeutic targets. To understand processes like hematopoietic differentiation and transformation, we must define the mechanisms regulating epigenetic modifiers. As the PAFc plays a role in hematopoiesis and several diseases, the proposed research will reveal the role of a previously uncharacterized epigenetic regulator complex in hematopoiesis while also defining how protein interactions, like SETDB1, module the PAFc function during hematopoietic differentiation.
染色质调控元件的表观遗传修饰深刻地影响着基因的表达并发挥着重要作用

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Andrew George Muntean其他文献

Andrew George Muntean的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Andrew George Muntean', 18)}}的其他基金

The role of the PAFc subunit Cdc73 in normal hematopoiesis and transformation
PAFc亚基Cdc73在正常造血和转化中的作用
  • 批准号:
    10408678
  • 财政年份:
    2018
  • 资助金额:
    $ 38.29万
  • 项目类别:
Post-translational regulation of MLL in leukemogenesis
MLL 在白血病发生中的翻译后调控
  • 批准号:
    8678870
  • 财政年份:
    2011
  • 资助金额:
    $ 38.29万
  • 项目类别:
Post-translational regulation of MLL in leukemogenesis
MLL 在白血病发生中的翻译后调控
  • 批准号:
    8546308
  • 财政年份:
    2011
  • 资助金额:
    $ 38.29万
  • 项目类别:
Post-translational regulation of MLL in leukemogenesis
MLL 在白血病发生中的翻译后调控
  • 批准号:
    8526834
  • 财政年份:
    2011
  • 资助金额:
    $ 38.29万
  • 项目类别:
Post-translational regulation of MLL in leukemogenesis
MLL 在白血病发生中的翻译后调控
  • 批准号:
    8089793
  • 财政年份:
    2011
  • 资助金额:
    $ 38.29万
  • 项目类别:
Post-translational regulation of MLL in leukemogenesis
MLL 在白血病发生中的翻译后调控
  • 批准号:
    8301560
  • 财政年份:
    2011
  • 资助金额:
    $ 38.29万
  • 项目类别:

相似海外基金

Understanding of the onset and recurrence pattern of intractable acute lymphocytic leukemia based on clone analysis
基于克隆分析了解难治性急性淋巴细胞白血病的发病和复发模式
  • 批准号:
    20K08723
  • 财政年份:
    2020
  • 资助金额:
    $ 38.29万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Novel Inhibitors of Multi-Drug-Resistant Mutants of BCR-ABL for the Treatment of Chronic Myelogenous Leukemia (CML) and Ph Positive Acute Lymphocytic Leukemia (ALL).
BCR-ABL 多重耐药突变体的新型抑制剂,用于治疗慢性粒细胞白血病 (CML) 和 Ph 阳性急性淋巴细胞白血病 (ALL)。
  • 批准号:
    9047400
  • 财政年份:
    2015
  • 资助金额:
    $ 38.29万
  • 项目类别:
The Role of Genetic Variants in Sensitivity to Methotrexate in Acute Lymphocytic Leukemia Survivors
遗传变异在急性淋巴细胞白血病幸存者对甲氨蝶呤敏感性中的作用
  • 批准号:
    319114
  • 财政年份:
    2014
  • 资助金额:
    $ 38.29万
  • 项目类别:
    Fellowship Programs
Targeting the Bone Marrow Microenvironment In Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的骨髓微环境
  • 批准号:
    8595788
  • 财政年份:
    2013
  • 资助金额:
    $ 38.29万
  • 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
  • 批准号:
    8023518
  • 财政年份:
    2011
  • 资助金额:
    $ 38.29万
  • 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
  • 批准号:
    8404025
  • 财政年份:
    2011
  • 资助金额:
    $ 38.29万
  • 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
  • 批准号:
    8220724
  • 财政年份:
    2011
  • 资助金额:
    $ 38.29万
  • 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
  • 批准号:
    8599754
  • 财政年份:
    2011
  • 资助金额:
    $ 38.29万
  • 项目类别:
INSULIN RESISTANCE IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA UNDERGOING INDUCT
正在接受治疗的急性淋巴细胞白血病儿童的胰岛素抵抗
  • 批准号:
    8356701
  • 财政年份:
    2010
  • 资助金额:
    $ 38.29万
  • 项目类别:
INSULIN RESISTANCE IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA UNDERGOING INDUCT
正在接受治疗的急性淋巴细胞白血病儿童的胰岛素抵抗
  • 批准号:
    8166720
  • 财政年份:
    2009
  • 资助金额:
    $ 38.29万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了